Diaceutics Partners With Global EQA Providers to Implement Best-in-class Testing Standards
Partnerships are on
Diaceutics’ DXRX platform – the world’s first diagnostic network for precision medicine
- Platform, launching in Q4 2020, has been purpose built to enable collaboration between key stakeholders in precision medicine to solve real-world biomarker testing issues
- Pharmaceutical companies will gain greater oversight of diagnostic testing standards for their new and planned precision medicines
- Will enable individual laboratories in Diaceutics’ global network of labs to benchmark test performances with labs across the globe, paving the way towards best-in-class testing on a global scale
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200928005047/en/
By partnering with CPQA-AQCP, EMQN CIC and NordiQC on DXRX – the world’s first diagnostic network for precision medicine – Diaceutics will support the implementation of accurate and high-quality testing across its 2500+ laboratory relationships.
These collaborations facilitate a critical piece of the end-to-end solution which DXRX enables for the development and commercialization of precision medicine diagnostics. They are also part of multiple partnerships which Diaceutics is building with industry providers across the globe to help achieve their mission of getting every patient the treatment they deserve.
Currently focused on the Canadian market, CPQA-AQCP is dedicated to monitoring and improving the proficiency of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) testing. DXRX is a global platform which will enable CPQA-AQCP to expand its services further worldwide. The organization is currently collaborating with Diaceutics on a project sponsoring the HER2 biomarker modules for gastric cancer. Using IHC and FISH, they are assessing the landscape and efficiency of HER2 gastric cancer testing, which has now been on the market for more than 10 years.
NordiQC is a global and scientific proficiency program for diagnostic Immunohistochemistry with more than 500 participants. NordiQC provides a broad range of relevant modules for immunohistochemical proficiency testing within diagnostic pathology and with special attention to predictive biomarkers. By joining the DXRX network, NordiQC strengthens its mission to bridge all stakeholders in diagnostic precision testing to optimize and standardize this field.
The addition of CPQA-AQCP, EMQN CIC and NordiQC on DXRX complements recent partnerships announced with
“Personalized medicine requires precision diagnostics to ensure the therapies are targeted accurately, thus providing optimum outcomes for patients. There is a greater demand on labs to provide prognostic biomarker testing of more esoteric targets and we, in EQA organizations, need to provide support for establishing the tests and for maintaining quality of the tests so that patients and their oncologists are confident that the most effective therapy is being used.
“Working with Diaceutics and its established partners is a great opportunity for CPQA-AQCP to assure accurate and sustainable pharma-diagnostic testing.”
Søren Nielsen, Director of NordiQC, said: “It’s with great expectations and excitement we enter the cooperation with Diaceutics. The partnership is driven by mutual interest and goal to raise and secure the global level of immunohistochemical precision testing and only by broad collaboration between laboratories, pharma, industry, regulatory bodies and EQA programs this can be accomplished.”
“We are delighted to have CPQA, EMQN CIC and NordiQC join the DXRX network to enable a critical piece of an end-to-end development and commercialization solution designed to get every patient the treatment they deserve.”
- Ends -
At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. Diaceutics has worked on every precision medicine brought to market and provides services to36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries. www.diaceutics.com
CPQA-AQCP partners with diagnostic medical laboratories to maintain a high standard of biomarker testing by providing samples that allow labs to test their performance.
CPQA-AQCP is one of the products of the evolution of the Canadian Immunohistochemistry Quality Control (CIQC), originally founded in 2009, in response to the ever-changing landscape of diagnostic medical laboratory testing in Canadian and international laboratories. CPQA-AQCP continues to build on existing work to systematically monitor and improve the proficiency of medical laboratory testing across the country, facilitating participation by laboratories nationwide and internationally regardless of jurisdiction or existing accreditation requirements.
About EMQN CIC
EMQN CIC is a leading authority in quality assurance, committed to helping ensure diagnostic molecular genetic laboratory test results are accurate, reliable and comparable – wherever they are produced. The organization was established in 1998 after a successful pilot trial of a Huntington disease EQA scheme the previous year. From
Nordic Immunohistochemical Quality Control (NordiQC) is a global and scientific proficiency program for diagnostic Immunohistochemistry. NordiQC provides a range of relevant modules for immunohistochemical proficiency testing comprising both well-established and newly introduced immunohistochemical markers with central diagnostic and predictive value. NordiQC actively cooperates with all stakeholders being laboratories, industry and regulatory bodies to promote and establish standards for immunohistochemical precision testing. NordiQC is affiliated to and based at
00353 1 2993000
Comit Communications & Marketing
00353 1 2993000